The firm's tried to shore up its position as the FDA and Health Canada cleared Phase II trials for its flagship psilocybin ...

The delay is at least the second such move by the USDA, the agency said in a press release, after it made a similar decision ...

The biotech reported progress on its lead molecule and out-licensed two candidates, amid cash constraints and a potential ...

The Toronto-based drugmaker's revenue held steady, helped by stronger performance from its Colombian operations.

The struggling psychedelics firm abandoned direct patient care in favor of developing tech for insurance reimbursement and ...